FutureChem has entered into a research agreement with the University of Colombia for the Parkinson's diagnostic radiopharmaceutical. Parkinson's diagnostic radiopharmaceutical PDvue, developed by FutureChem, is an F-18 isotope-labeled medicinal product. It has superior image quality and convenience compared to iodine (I-123) labeled drugs used in the US. The company is in the process of finalizing approval of the US FDA's Phase I clinical trial application (IND) by the end of the year.